While individuals taking semaglutide can still contract COVID-19, they had a 33% lower chance of dying from the sickness, according to a study published by the Journal of the American College of Cardiology at the end of August.
The studies also show that semaglutide can reduce a patient’s risk of serious heart events such as heart attacks and strokes.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
